Representative examples are the OVs derived from HSV (oHSVs): most of these OVs, including the FDA-approved T-VEC, are ablated for viral factors that counteract the IFN response so that they can replicate in IFN-defective cancer cells and not in IFN-competent healthy cells. This evidence concerns the gene IFNA1 and cancer.